Ireland
--:--IST
Recruiting Observational

Non Interventional German Leptomeningeal Disease Register

NCT06146010 · tracked via the Priya Life Science Germany tracker
Phase
Observational
Started
2024-06-26
Last updated
2026-04-08

Condition(s) studied

Meningeal NeoplasmsLeptomeningeal Disease

Investigational drug(s) / intervention(s)

No intervention

No intervention: Once the patient or their legal guardian has given their written consent, a patient is included in the leptomeningeal disease register. Due to the rapid course of the disease and potential rapid deterioration, the documentation of the course of the disease of the individual patients is to be carried out retrospectively from the data recorded during the course of the clinical routine for the entire duration of the study or until the death of the participating patients after the written consent of the patients. The registry's data sources are the diagnostic findings made at the center and doctors' letters from routine clinical practice. The participating centers carry out the assessment of the participants' performance status so that the patients do not have to complete any study-related questionnaires.

Study summary

The planned multicenter register is intended to create a database in the form of a cancer register on the incidence and course of disease in Germany of leptomeningeal disease, the therapeutic measures administered in the real world and the complications.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients with leptomeningeal disease * Written consent of the patient or legal guardian. * Capacity to give consent or legal guardianship * Age ≥ 18 years Exclusion Criteria: * Lack of informed consent from the patient * Lack of capacity to consent on the part of the person concerned or lack of legal guardianship * Age \< 18 years

Primary outcome measure(s)

  • Progression-free survival depending on the treatment modalities — through study completion, an average of 1 year
    Only descriptive analyses are planned for the data documented in the register. Absolute and percentage frequencies including two-sided 95% confidence intervals are determined for the frequency of use of certain treatment regimens.
  • Overall survival depending on the treatment modalities — through study completion, an average of 1 year
    Only descriptive analyses are planned for the data documented in the register. Absolute and percentage frequencies including two-sided 95% confidence intervals are determined for the frequency of use of certain treatment regimens.

Trial sites (7)

FacilityCityRegionStatus
Universitätsklinikum Bonn Klinik und Poliklinik für Neurologie Bonn Germany Recruiting
Universitätsmedizin Mannheim Universitätsklinikum Mannheim GmbH Klinik für Neurologie Mannheim Germany Recruiting
Klinikum rechts der Isar | Technische Universität München; Klinik für Radioonkologie und Strahlentherapie München Germany Recruiting
Überörtliche Gemeinschaftspraxis für Hämatologie und Onkologie Münster Germany Not Yet Recruiting
Diakonie Klinikum GmbH • Jung-Stilling-KrankenhausAbteilung Neurochirurgie Siegen Germany Recruiting
University Hospital Tübingen, Neurooncology Tübingen Germany Recruiting
Universitätsklinikum Ulm; Klinik für Innere Medizin III Ulm Germany Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06146010 on ClinicalTrials.gov ↗ ← All trials in Germany